Endologix (ELGX) Poster Smaller Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Endologix Reports Third Quarter 2019 Financial Results
November 6, 2019 4:02 PM ESTThird Quarter Highlights
Global revenue up 2.9% versus prior year Sequential AFX system sales increase in the U.S. Operating cash burn of $4.0M for the quarterÂ
IRVINE, Calif.--(BUSINESS WIRE)-- Endologix, Inc. (the Company) (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the third quarter ended September 30, 2019.
Our persistent focus on execution has resulted in improved performance across the business including AFX2 in the U.S., as evidenced by our... More



